In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
The mean rating for Clovis Oncology stock is 2.25, and its target price is $23.7, implying an upside potential of 57.2% over its closing price of $15.08 on November 14.
In comparison, peers AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), and Eli Lilly and Company (LLY) have mean ratings of 2.6, 1.79, and 2.33, respectively, and target prices of $100.58, $121.67, and $113.0, respectively.
Clovis Oncology’s long-term debt-to-equity ratio stands at 2.46. In comparison, the long-term debt to equity ratios of its peers Merck & Co. (MRK), BioMarin Pharmaceutical, and Eli Lilly and Company stand at 0.61, 0.28, and 0.89, respectively, indicating that Clovis has taken on higher levels of leverage than its peers.
Clovis Oncology’s cash per share stands at $11.44. In comparison, the cash per share of its peers AbbVie, BioMarin Pharmaceutical, and Eli Lilly and Company stand at $5.87, $7.87, and $8.69, respectively.
Clovis Oncology’s EV (enterprise value) is $795.39 million, and its EV-to-revenue ratio is 9.69. Its price-to-sales ratio is 9.68, and its price-to-book ratio is 3.40.